Latest Breaking News On - Disease specific epitopes - Page 1 : comparemela.com

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPromis neurosciences incExchange commissionPublishes study highlighting oligomer selectivityNeil warmaChief executive officerCollective coordinatesDisease specific epitopesPrivate securities litigation reform actAnnual reportUnited states securitiesInvestor relationsMarie fields

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNeil cashmanPromis neurosciences inc nasdaqPromis neurosciences incBiological chemistryInteraction between pathogenic proteinsTreatment targetNeurosciences incNeil warmaChief executive officerChief scientific officerCollective coordinatesDisease specific epitopesPrivate securities litigation reform actAnnual report

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomBloom burton coPromis neurosciences incUpcoming investor conferencesChief executive officerAnnual needham virtual healthcareHealthcare investor conferenceCollective coordinatesDisease specific epitopesInvestor relationsMarie fields

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology comp.

United kingdomUnited statesEuropean patent officeTrademark officeJapanese patent officeUniversity of british columbiaPromis neurosciences incUnited states patentNeil warmaChief executive officerBritish columbiaCollective coordinatesDisease specific epitopesPrivate securities litigation reform actAnnual reportPost effective amendment

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024. Presentation Details: Presen

New yorkUnited statesUnited kingdomMarriott marquisPromis neurosciences incNeil warmaChief executive officerPlymouth roomNew york marriottCollective coordinatesDisease specific epitopesInvestor relationsMarie fieldsBio ceo investor conferenceNeurodegenerative diseasesBiotechnology company